# Vitamin D3 (Cholecalciferol)

> Vitamin D3 is a fat-soluble hormone that regulates calcium, supports immune function, and stabilizes mast cells. About 51% of POTS patients run deficient; correcting the deficit produces mast cell stabilization and autonomic support that supplementation studies have repeatedly shown. ZebraThrive uses 2,000 IU daily, paired with K2 to route calcium correctly.

**Page:** https://www.wellnessforzebras.com/ingredients/vitamin-d3
**Brand:** ZebraThrive
**Author:** Ken Chapman, Founder of ZebraThrive
**Last reviewed:** 2026-05-11
**Daily dose:** 2,000 IU (50 mcg) daily
**Form used:** D3 (Cholecalciferol) - Oil-based
**Target population:** Adults 18+ with hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), or Mast Cell Activation Syndrome (MCAS).
**Regulatory framing:** US DSHEA dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## Key benefits

- 74% of pediatric POTS patients improved in clinical trial
- Reduces histamine release by 23-34%
- Deficiency linked to 36% higher orthostatic hypotension risk
- Nearly 2x faster wound healing in RCTs

## What it is

A fat-soluble hormone that regulates calcium, supports immune function, and stabilizes mast cells

## Why we include it

Addresses the high deficiency rate in POTS patients (51% are deficient) while providing mast cell stabilization and autonomic support

## Plain-language summary

Vitamin D3 (cholecalciferol) is the form your skin produces in response to sunlight and the form most studied in human trials. For the triad, D3 has the strongest direct POTS evidence of any ingredient on this list: a 2025 Chinese RCT in 65 pediatric POTS patients showed 74% symptom improvement with 800 IU daily for 2 months. Add in mast cell stabilization through VDR-mediated pathways and connective tissue support through tendon and wound-healing data, and D3 is one of the most evidence-backed inclusions. We dose 2,000 IU (50 mcg) in the AM with K2 - both fat-soluble, better absorbed with breakfast fat.

## Mechanism

Vitamin D3 acts as a neuroactive hormone with profound effects on multiple systems. In POTS patients, it modulates autonomic nervous system function-deficiency correlates with decreased heart rate variability and impaired baroreflex sensitivity. It enhances β-adrenergic signal transduction in cardiac cells and regulates the renin-angiotensin system.

For MCAS, vitamin D3 works as a mast cell stabilizer. Mast cells express both vitamin D receptors (VDR) and the enzyme CYP27B1, enabling local conversion to active calcitriol. Through VDR-dependent mechanisms, it suppresses histamine release and reduces inflammatory mediators including leukotrienes, TNF-α, and IL-6.

In connective tissue, vitamin D influences the hydroxylation processes essential for stable collagen cross-linking, working synergistically with vitamin C and iron. High deficiency rates in hEDS (60%) and POTS (51%) make supplementation particularly relevant.

## Condition-specific notes

### MCAS (Mast Cell Activation Syndrome)

Vitamin D3 stabilizes rather than triggers mast cells. It suppresses IgE-dependent activation and reduces histamine, tryptase, and inflammatory cytokine release. European expert consensus recommends continuing supplementation in mastocytosis/MCAS based on these mechanisms.

### hEDS (hypermobile Ehlers-Danlos Syndrome)

60% of hEDS patients show deficiency, often due to GI malabsorption. Vitamin D supports collagen synthesis and bone mineralization. For joint health, deficiency is linked to significantly higher surgical retear rates. It works synergistically with K2 to ensure proper calcium utilization.

### POTS (Postural Orthostatic Tachycardia Syndrome)

51% of POTS patients have levels below 20 ng/mL. The Chinese pediatric trial showed 74% improvement with supplementation. Heart rate variability markers may help identify those most likely to respond to Vitamin D.

## Why this form

**Selected form:** D3 (Cholecalciferol) - Oil-based

D3 consistently outperforms D2 (ergocalciferol) in raising and maintaining serum levels. Oil-based formulations show 30-50% better absorption compared to powders when taken with food.

**Form comparison:**

| Form | Notes | Selected |
|---|---|---|
| D3 (Cholecalciferol) | 3-5x more potent than D2; preferred form | Yes |
| D2 (Ergocalciferol) | Inferior bioavailability; shorter half-life | No |
| Oil-based liquid/capsule delivery | 30-50% better absorption than dry powder; descriptive of our delivery format | No |

## Dose protocol

| Step | Dosage | Notes |
|---|---|---|
| Weeks 1-2 | 1,000 IU daily | Ultra-sensitive start |
| Weeks 3-4 | 2,000 IU daily | Standard maintenance |
| Ongoing | 2,000-4,000 IU daily | Adjust based on labs |

**Timeline to effect:** Repletion takes 8-12 weeks; symptom improvement usually seen within 2-3 months. Take with fat-containing meal.

## Evidence summary

### POTS Symptom Improvement

Strong direct evidence from pediatric studies shows significant symptom improvement with supplementation.

- [1] **Dong et al., Lanzhou University.** Design: RCT, n=65 pediatric POTS patients. Finding: 74% improved with 800 IU/day; POTS patients had markedly lower baseline 25(OH)D levels.. PMID: 40962545.

### Orthostatic Hypotension Risk

Large meta-analysis confirms deficiency significantly increases orthostatic intolerance risk.

- [2] **Zuin et al..** Design: Meta-analysis, 16,326 patients. Finding: Vitamin D deficiency associated with 36% higher orthostatic hypotension risk (OR 1.36).. PMID: 34628636.

### Mast Cell Stabilization

Mechanistic studies demonstrate D3 suppresses activation through receptor-mediated pathways.

- [3] **Liu et al..** Finding: D3 suppresses IgE-dependent mast cell activation, reducing histamine release by 23-34%.. PMID: 27998003.

## Evidence gaps

No direct RCTs specifically in adult hEDS, POTS, or MCAS populations. Some findings are counterintuitive (e.g., higher vitamin D status in some MCAS cohorts). All autonomic benefits are extrapolated primarily from pediatric and diabetic populations.

## Safety

**Side effects:** Generally well-tolerated. Hypercalcemia is possible at very high doses (>10,000 IU) without monitoring. Some patients report initial paradoxical reactions, often excipient-related.

**Interactions:** No direct interactions with common POTS/MCAS meds. H2 blockers may slightly reduce absorption (space by 2 hours). Thiazide diuretics require calcium monitoring.

**Cautions:** Monitor serum 25(OH)D levels (target 40-60 ng/mL). Check serum calcium if taking high doses (>4,000 IU).

**Excipients to avoid:** FD&C dyes, Titanium dioxide, Carrageenan, Corn starch, BHA/BHT

**Excipients that are safe:** MCT oil, Olive oil, Minimal-ingredient liquid drops

## Frequently asked questions

### Do I really need to supplement vitamin D?

For this community, probably yes. The prevalence data is striking: 51% of POTS patients have D levels under 20 ng/mL, 56% under 30 ng/mL - significantly higher rates than the general population. EDS populations show similar patterns. MCAS is paradoxical - some cohorts have better D status - but European expert consensus still recommends supplementation. Most chronic illness compromises D status through reduced sun exposure, altered metabolism, and inflammation. 2,000 IU daily is the conservative maintenance dose.

### Will I need a higher D3 dose than 2,000 IU?

Possibly. 2,000 IU is the conservative maintenance dose - enough to keep most adults in the sufficient range (30-50 ng/mL serum 25(OH)D) if starting from sufficient. If starting deficient, you'll need a higher loading dose for 6-12 weeks before dropping to maintenance. Check your serum 25(OH)D at baseline and after 3 months on the formulation - if still under 30 ng/mL, add more D3 separately. The dose isn't one-size-fits-all; testing is the way to dial it in.

### Why D3 and K2 together?

They work as a pair: D3 increases calcium absorption from the gut, K2 (MK-7 form) activates the proteins that route that calcium to bones and teeth rather than arteries and soft tissues. The pairing is standard practice for any D3 dose above 1,000 IU daily, which is why both ship in the AM capsule together.

### What about vitamin D and mast cells?

The data is complex. The VDR-mediated mast cell mechanisms are real in lab studies, but MCAS cohorts paradoxically have better D status than the general population, so deficiency isn't the primary MCAS driver. The honest take: D3 doesn't cause MCAS, doesn't cure it, and the mast cell mechanisms are real. Continue supplementation, don't expect it to be the answer.

## References

[1] Dong et al.. (2025). Vitamin D supplementation in pediatric POTS. PMID: 40962545. https://pubmed.ncbi.nlm.nih.gov/40962545/
[2] Zuin et al.. (2022). Vitamin D deficiency and orthostatic hypotension meta-analysis. PMID: 34628636. https://pubmed.ncbi.nlm.nih.gov/34628636/
[3] Liu et al.. (2017). Vitamin D suppresses IgE-dependent mast cell activation. PMID: 27998003. https://pubmed.ncbi.nlm.nih.gov/27998003/
[4] Faria et al.. (2024). Vitamin D and autonomic function. PMID: 38747749. https://pubmed.ncbi.nlm.nih.gov/38747749/
[5] Busch et al.. (2016). Vitamin D deficiency in vascular EDS. PMID: 27488172. https://pubmed.ncbi.nlm.nih.gov/27488172/